Regulatory FDA Approves First New Molecular Entity Under National Priority Voucher Program FDAThe U.S.RegulatoryRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) FDA The U.S. RegulatoryRead full story Post navigation Previous: Ambrosia adds a megaround for obesity drugsNext: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026